| D008075 |
Lipoproteins, HDL |
A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. |
High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins |
|
| D008297 |
Male |
|
Males |
|
| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D011341 |
Probucol |
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). |
Biphenabid,DH-581,Lorelco,Lurselle,Panavir,Superlipid,DH 581,DH581 |
|
| D002995 |
Clofibric Acid |
An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. |
Clofibrinic Acid,2-(4-Chlorophenoxy)-2-methylpropionic Acid,NSC-1149,p-Chlorophenoxyisobutyrate,p-Chlorophenoxyisobutyric Acid,NSC 1149,NSC1149 |
|
| D004359 |
Drug Therapy, Combination |
Therapy with two or more separate preparations given for a combined effect. |
Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000960 |
Hypolipidemic Agents |
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. |
Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic |
|
| D001054 |
Apolipoproteins A |
Structural proteins of the alpha-lipoproteins (HIGH DENSITY LIPOPROTEINS), including APOLIPOPROTEIN A-I and APOLIPOPROTEIN A-II. They can modulate the activity of LECITHIN CHOLESTEROL ACYLTRANSFERASE. These apolipoproteins are low in atherosclerotic patients. They are either absent or present in extremely low plasma concentration in TANGIER DISEASE. |
Apo-A,ApoA |
|
| D001629 |
Bezafibrate |
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. |
Azufibrat,BM-15.075,Befibrat,Beza-Lande,Beza-Puren,Bezabeta,Bezacur,Bezafibrat PB,Bezafisal,Bezalip,Bezamerck,Béfizal,Cedur,Difaterol,Eulitop,Lipox,Reducterol,Regadrin B,Sklerofibrat,Solibay,durabezur,BM 15.075,BM15.075,Beza Lande,Beza Puren |
|